Trials / Conditions / Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma

Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma

6 registered clinical trials studyying Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without B NCT06393751	National Cancer Institute (NCI)	Phase 1 / Phase 2
Recruiting	Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity NCT05920798	Mayo Clinic	Phase 1 / Phase 2
Withdrawn	Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent NCT05295589	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients NCT05114421	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents NCT04739800	National Cancer Institute (NCI)	Phase 2
Completed	Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surg NCT02898207	National Cancer Institute (NCI)	Phase 1